receipt of In-principle Approval from Stock Exchange for Bonus Issue
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare has received in-principle approval from BSE to issue 9,77,90,908 bonus equity shares of Re.1 each in a 1:1 ratio, meaning one new share for every one existing share held. This effectively doubles the share count. The record date to identify eligible shareholders is Friday, 03 October 2025. The approval is subject to standard conditions including dematerialized allotment, payment of additional listing fees, and compliance with SEBI/MCA guidelines.
Shareholders of record on 03 October 2025 will receive one additional share for every share they hold, though the share price typically adjusts downward on a proportional basis post-ex-date, leaving overall value largely unchanged. Bonus issues of this size signal management confidence but are generally neutral to slightly positive for liquidity and retail accessibility.